Avellino’s mission is to ethically and securely collect, organize and share genetic data to maximize its predictive diagnostic and therapeutic benefits to accelerate positive outcomes for individuals worldwide. As a global leader in leveraging artificial intelligence-powered algorithms, Avellino’s diagnostics provide eye care professionals with personalized genetic data to predict eye disease, prevent disease progression and preserve vision. Its R&D team has made groundbreaking discoveries in early detection of oncology, a polygenic risk score for glaucoma, and a siRNA gene-silencing therapeutic for the treatment of granular corneal dystrophy type II. Avellino is headquartered in California, with operations in Korea, Japan and the United Kingdom.